DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Pulmonary-Allergy Drugs Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Pulmonary-Allergy Drugs Advisory Committee. This meeting was announced in the **Federal Register** of May 11, 2004 (69 FR 26169). The amendment is being made to reflect a change in the location portion of the meeting, a clarification in the agenda portion of the meeting, and a change in the procedure portion regarding the time for the open public hearing session. There are no other changes.

FOR FURTHER INFORMATION CONTACT:

Shalini Jain, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, FAX: 301–827–6776, or e-mail: jains@cder.fda.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512545. Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of May 11, 2004, FDA announced that a meeting of the Pulmonary-Allergy Drugs Advisory Committee will be held on June 10, 2004. On page 26170, in the first column, the location, agenda, and procedure portions of the meeting are amended to read as follows:

Location: Holiday Inn, Two Montgomery Village Ave., Gaithersburg, MD.

Agenda: The committee will discuss whether the use of chlorofluorocarbons (CFCs) as propellants in albuterol metered-dose inhalers (MDIs) is no longer an essential use under the criteria as set forth in the Code of Federal Regulations (21 CFR § 2.125(g)).

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 24, 2004. Oral presentations from the public will be scheduled between approximately 12:30 p.m. to 2:30 p.m. Time allotted for each presentation may be limited. Those

desiring to make formal oral presentations should notify the contact person by May 24, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

This notice is given under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: May 25, 2004.

William K. Hubbard,

Associate Commissioner for Policy and Planning.

[FR Doc. 04–12365 Filed 5–28–04; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS. **ACTION:** Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines) published in the Federal Register on April 11, 1988 (53 FR 11970), and revised in the Federal Register on June 9, 1994 (59 FR 29908) and on September 30, 1997 (62 FR 51118). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines

If any laboratory has withdrawn from HHS' National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600

Fishers Lane, Rockwall 2, Room 815, Rockville, Maryland 20857; 301–443–6014 (voice), 301–443–3031 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards that laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification, a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines, the following laboratories meet the minimum standards set forth in the Mandatory Guidelines:

ACL Laboratories 8901 W. Lincoln Ave. West Allis, WI 53227
414–328–7840 / 800–877–7016
(Formerly: Bayshore Clinical Laboratory)
ACM Medical Laboratory, Inc.
160 Elmgrove Park
Rochester, NY 14624
585–429–2264
Advanced Toxicology Network
3560 Air Center Cove, Suite 101

Memphis, TN 38118 901–794–5770 / 888–290–1150 Aegis Analytical Laboratories, Inc. 345 Hill Ave. Nashville, TN 37210 615–255–2400

Baptist Medical Center-Toxicology Laboratory 9601 I–630, Exit 7 Little Rock, AR 72205–7299 501–202–2783 (Formerly: Forensic Toxicology Laboratory

Baptist Medical Center) Clinical Reference Lab 8433 Quivira Rd. Lenexa, KS 66215–2802 800–445–6917

Diagnostic Services Inc., dba DSI 12700 Westlinks Dr. Fort Myers, FL 33913 239–561–8200 / 800–735–5416

DrugProof, Division of Dynacare/Laboratory of Pathology, LLC 1229 Madison St., Suite 500, Nordstrom Medical Tower Seattle, WA 98104 206-386-2661 / 800-898-0180 (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)

DrugScan, Inc. P.O. Box 2969, 1119 Mearns Rd. Warminster, PA 18974 215-674-9310

Dynacare Kasper Medical Laboratories* 10150-102 St., Suite 200

Edmonton, Alberta

Canada T5J 5E2

780-451-3702 / 800-661-9876

ElSohly Laboratories, Inc. 5 Industrial Park Dr. Oxford, MS 38655 662-236-2609

Express Analytical Labs 3405 7th Ave., Suite 106 Marion, IA 52302 319-377-0500

Gamma-Dynacare Medical Laboratories * A Division of the Gamma-Dynacare Laboratory Partnership 245 Pall Mall St.

London, ONT Canada N6A 1P4 519-679-1630

General Medical Laboratories 36 South Brooks St. Madison, WI 53715 608-267-6225

Kroll Laboratory Specialists, Inc.

1111 Newton St. Gretna, LA 70053

504-361-8989 / 800-433-3823 (Formerly: Laboratory Specialists, Inc.)

LabOne, Inc. 10101 Renner Blvd.

Lenexa, KS 66219

913-888-3927 / 800-873-8845

(Formerly: Center for Laboratory Services, a Division of LabOne, Inc.)

Laboratory Corporation of America Holdings 7207 N. Gessner Rd. Houston, TX 77040

713-856-8288 / 800-800-2387

Laboratory Corporation of America Holdings 69 First Ave.

Raritan, NJ 08869

908-526-2400 / 800-437-4986

(Formerly: Roche Biomedical Laboratories,

Laboratory Corporation of America Holdings 1904 Alexander Dr.

Research Triangle Park, NC 27709 919-572-6900 / 800-833-3984

(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

Laboratory Corporation of America Holdings 10788 Roselle Št.

San Diego, CA 92121 800-882-7272

(Formerly: Poisonlab, Inc.)

Laboratory Corporation of America Holdings

1120 Stateline Rd. West Southaven, MS 38671

866-827-8042 / 800-233-6339

(Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center)

Marshfield Laboratories Forensic Toxicology Laboratory 1000 North Oak Ave. Marshfield, WI 54449

715-389-3734 / 800-331-3734

MAXXAM Analytics Inc. * 5540 McAdam Řd. Mississauga, ON Canada L4Z 1P1 905-890-2555

(Formerly: NOVAMANN (Ontario) Inc.)

MedTox Laboratories, Inc. 402 W. County Rd. D St. Paul, MN 55112 651-636-7466 / 800-832-3244

MetroLab-Legacy Laboratory Services 1225 NE 2nd Ave.

Portland, OR 97232

503-413-5295 / 800-950-5295

Minneapolis Veterans Affairs Medical Center Forensic Toxicology Laboratory

1 Veterans Dr.

Minneapolis, MN 55417

612-725-2088

National Toxicology Laboratories, Inc.

1100 California Ave. Bakersfield, CA 93304

661-322-4250 / 800-350-3515

Northwest Drug Testing, a division of NWT

1141 E. 3900 S.

Salt Lake City, UT 84124 801-293-2300 / 800-322-3361

(Formerly: NWT Drug Testing, NorthWest Toxicology, Inc.)

One Source Toxicology Laboratory, Inc. 1213 Genoa-Red Bluff

Pasadena, TX 77504

888-747-3774

(Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)

Oregon Medical Laboratories P.O. Box 972, 722 East 11th Ave. Eugene, OR 97440-0972

541-687-2134

Pacific Toxicology Laboratories

9348 DeSoto Ave.

Chatsworth, CA 91311

800-328-6942

(Formerly: Centinela Hospital Airport Toxicology Laboratory)

Pathology Associates Medical Laboratories 110 West Cliff Dr.

Spokane, WA 99204

509-755-8991 / 800-541-7891x8991

PharmChem Laboratories, Inc.

4600 N. Beach

Haltom City, TX 76137

817-605-5300

(Formerly: PharmChem Laboratories, Inc., Texas Division; Harris Medical Laboratory)

Physicians Reference Laboratory

7800 West 110th St. Overland Park, KS 66210

913-339-0372 / 800-821-3627

Quest Diagnostics Incorporated 3175 Presidential Dr. Atlanta, GA 30340

770-452-1590/800-729-6432

(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated

4770 Regent Blvd. Irving, TX 75063 800-824-6152

(Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated 4230 South Burnham Ave., Suite 250 Las Vegas, NV 89119-5412 702-733-7866/800-433-2750 (Formerly: Associated Pathologists Laboratories, Inc.)

Quest Diagnostics Incorporated 400 Egypt Rd.

Norristown, PA 19403

610-631-4600/877-642-2216

(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated 506 E. State Pkwy. Schaumburg, IL 60173 800-669-6995/847-885-2010

(Formerly: SmithKline Beecham Clinical Laboratories; International Toxicology Laboratories) Quest Diagnostics Incorporated

7600 Tyrone Ave. Van Nuys, CA 91405 818-989-2520/800-877-2520

(Formerly: SmithKline Beecham Clinical Laboratories)

Scientific Testing Laboratories, Inc. 450 Southlake Blvd.

Richmond, VA 23236

804-378-9130

Sciteck Clinical Laboratories, Inc. 317 Rutledge Rd.

Fletcher, NC 28732 828-650-0409

S.E.D. Medical Laboratories 5601 Office Blvd.

Albuquerque, NM 87109

^{*} The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspection of those LAPSAaccredited laboratories was transferred to the U.S. HHS, with the HHS' NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (**Federal Register**, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on June 9, 1994 (59 FR 29908) and on September 30, 1997 (62 FR 51118). After receiving DOT certification, the laboratory will be included in the monthly list of HHS certified laboratories and participate in the NLCP certification maintenance program.

505–727–6300/800–999–5227 South Bend Medical Foundation, Inc. 530 N. Lafayette Blvd. South Bend, IN 46601 574–234–4176 x276

Southwest Laboratories 2727 W. Baseline Rd. Tempe, AZ 85283

602-438-8507/800-279-0027

Sparrow Health System Toxicology Testing Center, St. Lawrence Campus

1210 W. Saginaw Lansing, MI 48915 517–377–0520

(Formerly: St. Lawrence Hospital & Healthcare System)

St. Anthony Hospital Toxicology Laboratory 1000 N. Lee St. Oklahoma City, OK 73101

405–272–7052

Toxicology & Drug Monitoring Laboratory University of Missouri Hospital & Clinics 301 Business Loop 70 West, Suite 208 Columbia, MO 65203 573–882–1273

Toxicology Testing Service, Inc. 5426 N.W. 79th Ave. Miami, FL 33166 305–593–2260

U.S. Army Forensic Toxicology Drug Testing Laboratory 2490 Wilson St. Fort George G. Meade, MD 20755–5235 301–677–7085

Patricia Bransford,

Director, Division of Management Systems, SAMHSA.

[FR Doc. 04–12237 Filed 6–1–04; 8:45 am]

BILLING CODE 4160-20-P

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary

Homeland Security Advisory Council

AGENCY: Office of the Secretary, Department of Homeland Security. **ACTION:** Notice of Federal Advisory Committee meeting.

SUMMARY: The Homeland Security
Advisory Council (HSAC) will hold its
next meeting in Washington, DC on
Thursday, June 17, 2004. The HSAC
will meet for purposes of: (1)
Welcoming and swearing in new
members; (2) deliberation on
recommendations of the Task Force on
State and Local Funding; (3) receiving
reports from Senior Advisory
Committees; (4) receiving briefings from
DHS staff on Departmental initiatives;
and (5) holding roundtable discussions
with and among HSAC members.

This meeting will be partially closed; the open portions of the meeting for purposes of (1) through (3) above will be held at the U.S. Secret Service Headquarters, 950 H Street, NW., Washington, DC from 10 a.m. to 12 p.m. The closed portions of the meeting, for purposes of (4) and (5) above will be held at the U.S. Secret Service Headquarters from 9 a.m. to 9:50 a.m. and from 12:10 p.m. to 3 p.m.

Public Attendance: A limited number of members of the public may register to attend the public session on a firstcome, first-served basis per the procedures that follow. Security requires that any member of the public who wishes to attend the public session provide his or her name, social security number, and date of birth no later than 5 p.m. EST, Friday, June 11, 2004. Please provide the required information to Mike Miron or Jeff Gaynor of the HSAC staff, via e-mail at HSAC@dhs.gov, or via phone at (202) 692–4283. Persons with disabilities who require special assistance should indicate so in their admittance request. Photo identification will be required for entry into the public session, and everyone in attendance must be present and seated by 9:45 a.m.

Basis for Člosure: In accordance with section 10(d) of the Federal Advisory Committee Act, Public Law 92–463, as amended (5 U.S.C. App. 2), the Secretary has issued a determination that portions of this HSAC meeting will concern matters sensitive to homeland security within the meaning of 5 U.S.C. 552b(c)(7) and (c)(9)(B) and that, accordingly, these portions of the meeting will be closed to the public.

Public Comments: Members of the public who wish to file a written statement with the HSAC may do so by mail to Mike Miron at the following address: Homeland Security Advisory Council, Department of Homeland Security, Washington, DC 20528. Comments may also be sent via e-mail to HSAC@dhs.gov or via fax at (202) 772–9718.

Dated: May 28, 2004.

Tom Ridge,

Secretary of Homeland Security.
[FR Doc. 04–12610 Filed 6–1–04; 8:45 am]
BILLING CODE 4410–10–P

DEPARTMENT OF THE INTERIOR

Office of the Secretary

National Satellite Land Remote Sensing Data Archive (NSLRSDA) Advisory Committee; Notice of Reestablishment

This notice is published in accordance with section 9(a)(2) of the Federal Advisory Committee Act (Public

Law 92–463), 5 U.S.C. App. (1988). Following consultation with the General Services Administration, notice is hereby given that the Secretary of the Interior is reestablishing the National Satellite Land Remote Sensing Data Archive (NSLRSDA) Advisory Committee. The NSLRSDA was established by Congress in the Land Remote Sensing Policy Act of 1992, Public Law 102–555, 15 U.S.C. 5601.

The purpose of the Committee is to advise the U.S. Geological Survey (USGS), Earth Resources Observation Systems (EROS) Data Center (EDC), on guidelines or rules relating to the NSLRSDA archival data deposit, maintenance, and preservation as well as access management policies and procedures. The Committee will be responsible for providing advice and consultation on a broad range of technical and policy topics in guiding development of NSLRSDA.

In order for the Secretary to be advised by a broad spectrum of remote sensing data users and producers, committee membership will be composed of 15 members, as follows: Two from academia, with one laboratory researcher-data user and one classroom educator-data user; four from government, with two Federal data users and two State/local data users; four from industry, with two licensed data providers, one value-added industruy provider, and one commercial industry provider; and five others, with one non-USA representative and four non-affiliated Individuals at-large from any sector. Expertise in information science, natural science, social science, and policy/law are represented within the sectors listed above.

The Committee will function solely as an advisory body and in compliance with the provisions of the Federal Advisory Committee Act. The Charter will be filed under the Act, 15 days from the date of publication of this notice.

Further information regarding the NSLRSDA Advisory Committee may be obtained from the Director, USGS, Department of the Interior, 12201 Sunrise Valley Drive, Reston, Virginia, 20192. Certification of reestablishment is published below.

Certification

I hereby certify that the reestablishment of the National Satellite Land Remote Sensing Data Archive Advisory Committee is necessary and in the public interest in connection with the performance of duties by the Department of the Interior mandated pursuant to the Land Remote Sensing Policy Act of 1992, Public Law 102–555, 15 U.S.C. 5601.